Answers are grounded in this paper and cite their sources.
Patients treated with Fms-like tyrosine kinase 3 (FLT3) inhibitor-based acute myeloid leukemia therapies nearly always develop resistance. In this issue, Alotaibi and colleagues describe the patterns of mutations that emerge upon relapse after FLT3 inhibitor therapy after initial response, as well as in treatment-refractory disease in a single-institution study; the findings offer insights for sequential therapies targeting the dominant clone at the time of relapse. See related article by Alotaibi et al., p. 125.
No takes yet. Share an insight, caveat, or question.
Shastri et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: